Integrated Multi-Omic Analysis Reveals Novel Subtype-Specific Regulatory Interactions in Pediatric B-Cell Acute
Irina Pushel1,2, Zachary S Clark3, Lisa A Lansdon2,4
1Genomic Medicine Center, Children's Mercy Kansas City, Kansas City, MO 64108, USA.
Cancers
|March 14, 2026
Summary
This study integrates multi-omics data for pediatric B-cell acute lymphoblastic leukemia (B-ALL), identifying novel biomarkers and a potential new target in calcium signaling for Ph-like B-ALL.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Pediatric B-cell acute lymphoblastic leukemia (B-ALL) benefits from molecular subtyping for targeted therapies.
- Proteomic landscape of B-ALL remains underexplored despite proteins being key therapeutic targets.
Purpose of the Study:
- To characterize the proteomic and phosphoproteomic profiles of Ph-like (BCR::ABL1-like) and ETV6::RUNX1 B-ALL subtypes.
- To integrate multi-omic data for novel biomarker discovery and understanding leukemogenesis.
Main Methods:
- Multi-omic integration of transcriptomic, proteomic, and phosphoproteomic data.
- Analysis of samples from pediatric B-ALL patients with Ph-like and ETV6::RUNX1 subtypes.
Main Results:
- Recapitulated known transcriptomic findings for B-ALL subtypes.
- Identified novel subtype-specific proteomic and phosphoproteomic biomarkers.
- Uncovered a potential role for calcium-dependent signaling in Ph-like B-ALL.
Conclusions:
- Calcium-dependent signaling pathways represent a novel therapeutic target for Ph-like B-ALL.
- Integrated multi-omics approach enhances precision medicine for pediatric leukemia.
- Unraveled regulatory interactions driving subtype-specific leukemogenesis.
